NUVB Nuvation Bio Inc.
Nuvation Bio Inc. (NUVB) is expected to report earnings on November 5, 2026, before the market open. The consensus earnings estimate is a loss of $0.12 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +2.6% since its last earnings release on August 6, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Nuvation Bio Inc.
Nuvation Bio is a global oncology company focused on tackling some of the toughest challenges in cancer treatment with the goal of developing therapies that create a profound, positive impact on patients’ lives.
Sector
Healthcare
Industry
Biotechnology